Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis

Multiple Sclerosis

Volumn 21, Issue 10, 2015, Pages 1262-1270

  Haghikia, Aiden ^a   Faissner, Simon ^a   Pappas, Derek ^b   Pula, Bartosz ^a   Akkad, Denis A ^c   Arning, Larissa ^c   Ruhrmann, Sabrina ^a   Duscha, Alexander ^a   Gold, Ralf ^a   Baranzini, Sergio E ^b   Malhotra, Sunny ^d   Montalban, Xavier ^d   Comabella, Manuel ^d   Chan, Andrew ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

disease modifying therapy (DMT); immune cellular energy metabolism; interferon ; Multiple sclerosis; oxidative phosphorylation; PGC 1

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHYTOHEMAGGLUTININ; THYMINE; TRANSCRIPTOME;

ADULT; ALLELE; ARTICLE; CD4+ T LYMPHOCYTE; CELL LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INTRACELLULAR ADENOSINE TRIPHOSPHATE; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MULTIPLE SCLEROSIS; OXIDATIVE PHOSPHORYLATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PGC 1 ALPHA GENE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; VALIDATION STUDY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; MONOCYTE; MONONUCLEAR CELL; PROCEDURES; ENERGY METABOLISM; FLOW CYTOMETRY; LUCIFERASE ASSAY;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MITOCHONDRIA; MONOCYTES; MULTIPLE SCLEROSIS;

EID: 84985946816     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514561909     Document Type: Article

References (35)

1. Calabrese M, Bernardi V, Atzori M,. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler 2012; 18: 418-424.
2. Schwid SR, Panitch HS,. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007; 29: 2031-2048.
3. Alexander JS, Harris MK, Wells SR,. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010; 16: 801-809.
4. Kvarnström M, Ydrefors J, Ekerfelt C,. Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-'3, IL-4 or IL-13. J Neurol Sci 2013; 325: 79-85.
5. Croze E, Yamaguchi KD, Knappertz V,. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 2013; 13: 443-451.
6. Brendecke SM, Prinz M,. How type I interferons shape myeloid cell function in CNS autoimmunity. J Leukoc Biol 2012; 92: 479-488.
7. Fox CJ, Hammerman PS, Thompson CB,. Fuel feeds function: Energy metabolism and the T-cell response. Nat Rev Immunol 2005; 5: 844-852.
8. Haghikia A, Hohlfeld R, Gold R,. Therapies for multiple sclerosis: Translational achievements and outstanding needs. Trends Mol Med 2013; 19: 309-319.
9. Wu Z, Puigserver P, Andersson U,. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115-124.
10. Haghikia A, Perrech M, Pula B,. Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PloS One 2011; 6: e18506.
11. Che HV, Metzger S, Portal E,. Localization of sequence variations in PGC-1α influence their modifying effect in Huntington disease. Mol Neurodegener 2011; 6: 1.
12. Weydt P, Soyal SM, Gellera C,. The gene coding for PGC-1 alpha modifies age at onset in Huntington's Disease. Mol Neurodegener 2009; 4: 3.
13. Taherzadeh-Fard E, Saft C, Andrich J,. PGC-1 alpha as modifier of onset age in Huntington disease. Mol Neurodegener 2009; 4: 10.
14. Arning L, Haghikia A, Taherzadeh-Fard E,. Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) 2010; 88: 431-436.
15. Falchi AM, Isola R, Diana A,. Characterization of depolarization and repolarization phases of mitochondrial membrane potential fluctuations induced by tetramethylrhodamine methyl ester photoactivation. FEBS J 2005; 272: 1649-1659.
16. Chan A, Seguin R, Magnus T,. Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: Termination of CNS autoimmune inflammation and modulation by interferon-beta. Glia 2003; 43: 231-242.
17. Fernald GH, Knott S, Pachner A,. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol 2007; 178: 5076-5085.
18. Byun E, Caillier SJ, Montalban X,. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344.
19. Sottong PR, Rosebrock JA, Britz JA,. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 2000; 7: 307-311.
20. Nickel P, Bestard O, Volk H,. Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr Opin Organ Transplant 2009; 14: 426-431.
21. Galligan CL, Pennell LM, Murooka TT,. Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult Scler 2010; 16: 1458-1473.
22. + T cells derived from RRMS and PPMS patients. Mult Scler 2012; 18: 674-678.
23. Kovarik P, Sauer I, Schaljo B,. Molecular mechanisms of the anti-inflammatory functions of interferons. Immunobiology 2007; 212: 895-901.
24. Prinz M, Kalinke U,. New lessons about old molecules: How type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol Med 2010; 16: 379-386.
25. Weinstock-Guttman B, Badgett D, Patrick K,. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171: 2694-2702.
26. Killestein J, Polman CH,. Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011; 7: 221-228.
27. Vega RB, Huss JM, Kelly DP,. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000; 20: 1868-1876.
28. Puigserver P, Rhee J, Donovan J,. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-555.
29. Witte ME, Nijland PG, Drexhage JAR,. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 2013; 125: 231-243.
30. St-Pierre J, Drori S, Uldry M,. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006; 127: 397-408.
31. Weydt P, Soyal SM, Landwehrmeyer GB,. A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurol 2014; 14: 1.
32. Eschbach J, Schwalenstöcker B, Soyal SM,. PGC-1α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet 2013; 22: 3477-3484.
33. Polman CH, Bertolotto A, Deisenhammer F,. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740-750.
34. Durelli L, Barbero P, Bergui M,. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79: 646-651.
35. Pappas DJ, Coppola G, Gabatto PA,. Longitudinal system-based analysis of transcriptional responses to type I interferons. Physiol Genomics 2009; 38: 362-371.